SEC Filings
State Street Reports 5.1% Cytokinetics Stake As Heart-Drug Label Decision Awaits FDA
The passive holding covers 7,143,229 shares; Cytokinetics awaits a decision on adding comparative trial results to Myqorzo's label.
SEC Filings
The passive holding covers 7,143,229 shares; Cytokinetics awaits a decision on adding comparative trial results to Myqorzo's label.
SEC Filings
The passive holding represents 4.1% of the common-stock class as CytomX prepares an approval-supporting cancer study.
SEC Filings
Sales increased 14.7% from September, bringing January–October revenue to NT$4.5 trillion.
SEC Filings
The voucher would cover one application from its late-stage oncology pipeline, while Comirnaty remains its one marketed product.
SEC Filings
The passive stake covered 33,523,019 shares as of September 30, against a recovery in Accenture's stock.
SEC Filings
The passive holding totals 7,650,889 shares, while Acadia awaits a ruling on protection for its NUPLAZID capsule formulation.
SEC Filings
The position covered 13,675,348 shares as of September 30, against the backdrop of ADMA's recent rally.
SEC Filings
The September position accompanies stronger cash generation and lower debt, while Albemarle faces pressure from lithium prices.
SEC Filings
The passive holding comes as Allegion expands its Americas business and expects 9.5–10.5% total revenue growth in 2026.
SEC Filings
The aircraft-parts maker expects 14% sales growth at the midpoint of its fiscal 2027 forecast.
SEC Filings
The passive holding covered 1,614,059 shares as of September 30, before the chip supplier's recent earnings-driven rally.
SEC Filings
The September 30 holding covered 16.3 million shares; Allogene released initial autoimmune-treatment trial results Monday.